State Street Corp Axcella Health Inc. Transaction History

State Street Corp

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	BUY	$1.58 - $2.82 $10,421 - $18,600	6,596 Added 9.33%	77,272 $199,000
Q2 2021 Aug 16, 2021	SELL	$3.08 - $5.13 $472,552 - $787,075	-153,426 Reduced 68.46%	70,676 $283,000
Q1 2021 May 17, 2021	BUY	$4.55 - $6.72 $67,403 - $99,550	14,814 Added 7.08%	224,102 $1.07 Million
Q4 2020 Feb 16, 2021	BUY	$4.24 - $5.97 $39,008 - $54,924	9,200 Added 4.6%	209,288 $1.09 Million
Q3 2020 Nov 10, 2020	BUY	$4.12 - $5.91 $240,027 - $344,310	58,259 Added 41.08%	200,088 $924,000
Q2 2020 Aug 14, 2020	BUY	$2.94 - $7.7 $76,628 - $200,692	26,064 Added 22.51%	141,829 $784,000
Q1 2020 May 11, 2020	BUY	$2.25 - $5.24 $260,471 - $606,608	115,765 New	115,765 $396,000

61.6K

Ticker AXLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,500,896
Description
Axcella Health Inc. operates as a clinical stage biotechnology company in the United States. The company treats complex diseases and enhances health using endogenous metabolic modulator compositions. Its lead product candidates include AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrenc...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.